Zenosense, Inc. (ZENO) Looks to Revolutionize Earl
Post# of 53
Posted On: 02/18/2015 5:23:35 PM
Zenosense, Inc. (ZENO) Looks to Revolutionize Early Lung Cancer Diagnosis
Less than 20 percent of lung cancer cases are detected in the relatively treatable Stage I, but healthcare technology company Zenosense, Inc. (OTCQB: ZENO) is hoping to change that. On December 16, 2014, the company announced its intention to conduct a 400 person lung cancer detection trial in collaboration with a university hospital near Madrid, Spain. Using its proprietary non-invasive, cost effective detection devices, the company aims to identify distinctive volatile organic compounds (VOCs) by analyzing patients’ exhaled breath.
Zenosense is hoping to use a technique based on natural processes to decrease the costs associated with lung cancer detection. Sniffing out diseases is a proven diagnostic method, as highly trained dogs have been used in the past to recognize the VOCs associated with prostate cancer with 98 percent accuracy. In the same way, the company’s device uses a great number of sensors to detect VOCs that are unique to a particular illness, such as lung cancer.
“I believe that a cost-effective lung cancer detector proven as meeting or exceeding the accuracy of low dose Computed Tomography (CT) scanning will have wide appeal and be in significant demand,” said Carlos Gil, Chief Executive Officer of Zenosense.
Zenosense expects the trial to take nine months, during which the company will examine samples from multiple groups to ensure proper functionality. If successful, the company intends to increase the size of the trial population in the future.
According to the American Cancer Society, there will be approximately 221,000 new cases of lung cancer, as well as an estimated 158,000 lung cancer related deaths, in the United States during this year alone. The same report indicates that patients who had their cancer diagnosed during Stage I development had an increased 5-year survival rate of approximately 61 percent over those who were diagnosed in Stage II.
With Zenosense’s lung cancer detection trial officially scheduled, a significant step forward in diagnostic techniques and lung cancer survivability could be just around the corner.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Less than 20 percent of lung cancer cases are detected in the relatively treatable Stage I, but healthcare technology company Zenosense, Inc. (OTCQB: ZENO) is hoping to change that. On December 16, 2014, the company announced its intention to conduct a 400 person lung cancer detection trial in collaboration with a university hospital near Madrid, Spain. Using its proprietary non-invasive, cost effective detection devices, the company aims to identify distinctive volatile organic compounds (VOCs) by analyzing patients’ exhaled breath.
Zenosense is hoping to use a technique based on natural processes to decrease the costs associated with lung cancer detection. Sniffing out diseases is a proven diagnostic method, as highly trained dogs have been used in the past to recognize the VOCs associated with prostate cancer with 98 percent accuracy. In the same way, the company’s device uses a great number of sensors to detect VOCs that are unique to a particular illness, such as lung cancer.
“I believe that a cost-effective lung cancer detector proven as meeting or exceeding the accuracy of low dose Computed Tomography (CT) scanning will have wide appeal and be in significant demand,” said Carlos Gil, Chief Executive Officer of Zenosense.
Zenosense expects the trial to take nine months, during which the company will examine samples from multiple groups to ensure proper functionality. If successful, the company intends to increase the size of the trial population in the future.
According to the American Cancer Society, there will be approximately 221,000 new cases of lung cancer, as well as an estimated 158,000 lung cancer related deaths, in the United States during this year alone. The same report indicates that patients who had their cancer diagnosed during Stage I development had an increased 5-year survival rate of approximately 61 percent over those who were diagnosed in Stage II.
With Zenosense’s lung cancer detection trial officially scheduled, a significant step forward in diagnostic techniques and lung cancer survivability could be just around the corner.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)